期刊文献+

沙利度胺联合VAD化疗方案治疗多发性骨髓瘤的疗效观察 被引量:2

下载PDF
导出
摘要 目的观察沙利度胺联合VAD方案治疗多发性骨髓瘤的临床疗效及不良反应。方法30例多发性骨髓瘤患者用沙利度胺联合VAD方案治疗,沙利度胺起始剂量为100mg/d,每周增加50mg/d,最大剂量为400mg/d,持续12周以上;VAD方案,长春新碱0.4mg/d静脉滴注第1~4天;表阿霉素10mg/d静脉滴注第1~4天;地塞米松40mg/d静脉滴注第1~4天、第9~12天和第17~21天。28d为1疗程,共3个疗程。结果30例患者中,部分缓解18例(60%),进步8例(26.7%),无效4例(13.3%),有效率86.7%。不良反应主要有便秘和嗜睡头昏等。结论沙利度胺联合VAD方案治疗多发性骨髓瘤具有不良反应少、耐受性好、疗效明显等优点。
作者 吴文淼 陆滢
机构地区 宁波市第一医院
出处 《现代实用医学》 2007年第9期698-698,700,共2页 Modern Practical Medicine
  • 相关文献

参考文献4

  • 1Barlogie B,Smith L,Alexanian R.Effective treatment of advanced multiple myeloma refractory to alkylating agents[J].N Engl J Med,1984,310(21):1353-1356.
  • 2Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21):1565-1571.
  • 3Lelen X,Magro L,Fawaz A,et al.Efficacy of a lowdose of thalidomide in advanced multiple myeloma[J ].Blood,2002,100(4):1519.
  • 4杨强,周棠馨.小剂量反应停治疗复发难治多发性骨髓瘤[J].四川医学,2005,26(2):201-202. 被引量:5

二级参考文献4

共引文献4

同被引文献18

  • 1徐岚,韩洁英,钟璐,钟华,黄洪晖,陈芳源,欧阳仁荣.VAD方案治疗初发的多发性骨髓瘤临床疗效观察[J].中国癌症杂志,2005,15(1):70-71. 被引量:10
  • 2麦玉洁,李睿,邹德慧,王亚非,赵耀中,杨仁池,王建祥,肖志坚,韩明哲,钱林生,邱录贵.206例多发性骨髓瘤患者不同方案疗效分析[J].中华血液学杂志,2005,26(4):193-196. 被引量:37
  • 3郑翠苹,张卫平,徐杰.沙立度胺联合MP化疗方案治疗多发性骨髓瘤23例[J].临床血液学杂志,2005,18(5):277-278. 被引量:3
  • 4Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [ J ]. Blood, 2001,98 (5) :210-216.
  • 5Gardyn J. Thalidomide with continuous low-dose dexamethasone for multiple myeloma [ J ]. J Clin Oncol, 2005,23 (2) : 1323-1325.
  • 6Jagannath S, Durie BG, Woif J, et al. Bortezomih therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma [ J ]. Br J Haematol, 2005,129 ( 6 ) : 776-3783.
  • 7Sanchez-Guijo FM, Sanchez-Abarca LI.Posttransplant hematopoiesis in patients undergoing sibling allogeneie stem cell transplantation reflects that of their respective donors although with a lower functional capability [ J ]. Exp Hematol, 2005,33 ( 7 ) : 935-943.
  • 8BarlogieB, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 1997, 89 (3): 789-793.
  • 9LenhoffS, Hjorth M, Holmberg E, et aI. Impact on survival of high-dose therapy with autologous stemcell support in patients younger than 60 years with newly diagnosd multiple myeloma: apopulation-based study. Blood, 2000, 95 ( 1 ): 7-11.
  • 10Palumbo A, Bring, hen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 2006, 367 (9513): 825-831.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部